#Ireland #Dublin #Heart Failure #FIRE1 #Norm System

FIRE1 Launches NORM-HF Trial

FIRE1, a pioneering company in connected medical device solutions, announced on September 30, 2026, that it has initiated the enrollment of the first patients for its NORM-HF pivotal trial. This groundbreaking trial is an international, multicenter, randomized study aimed at revolutionizing heart failure management through a new physiologically guided approach.

Overview of the NORM-HF Trial

The NORM-HF trial will participate approximately 800 patients across multiple centers, investigating the innovative Norm™ System. This system focuses on daily monitoring of the inferior vena cava (IVC) to detect physiological changes related to heart congestion. The underlying principle is that early detection of worsening congestion enables proactive management of heart failure, allowing patients to mitigate deterioration before it becomes critical.

Key Features of the Norm™ System

The Norm System consists of a small implanted sensor placed in the inferior vena cava. This device dynamically measures changes in the IVC size and collapsibility, offering real-time insights into a patient’s volume status and venous congestion. Patients will utilize a connected application on their devices to receive personalized Norm Congestion Scores based on their daily readings, which empower them to make informed decisions about their treatment plans under a physician prescribed guideline.

The Innovative Care Model

This trial seeks to assess the effectiveness of combining physiologically guided monitoring and patient self-management versus the standard approach to heart failure care. Unlike existing implanted monitoring systems that necessitate substantial clinician oversight and intervention, the Norm System is designed for simplicity and accessibility. Patients will be able to adjust their treatment protocols directly via the application while maintaining a connection with their healthcare team.

Implications for Heart Failure Management

Heart failure is a condition affecting over 6.7 million individuals in the United States alone, representing a major burden on both healthcare resources and patient quality of life. Monitoring tools play a vital role in managing heart failure, primarily targeting the identification of fluid retention that signifies deteriorating heart function.

The NORM-HF trial aims to establish whether this pioneering approach of daily physiologic assessment can lead to earlier interventions that could reduce the frequency of hospitalizations and improve overall patient outcomes. Dr. James Udelson, Chief of Cardiology at Tufts Medical Center and a principal investigator of the study, highlights the potential for patients to directly influence their treatment based on the insights offered by the Norm System.

Empowering Patient Engagement

Unlike previous trials where decisions largely rested with healthcare providers, NORM-HF encourages active patient engagement, empowering them to modify their medications based on the signals from the device. This shift marks a transformative potential in heart failure care, where daily assessments serve as a preventive measure against symptoms that often lead to severe complications.

Conclusion

As FIRE1 embarks on this significant trial, the hope is to validate a care model that not only enhances clinical outcomes but also promotes patient independence. By advancing our understanding of real-time heart function, the NORM-HF trial could reshape the future of heart failure treatment, making a profound difference in the lives of millions suffering from this chronic condition.

For more detailed information, visit FIRE1's website.